Abstract
OBJECTIVES In Japan, when bevacizumab was approved for malignant glioma patients in 2013, there were limited data on Japanese patients. In the global P3 AVAglio study, the incidence of cerebral hemorrhage, including tumor-related bleeding, and infections was higher in patients who received bevacizumab. This surveillance study was conducted to assess the safety and effectiveness of bevacizumab in patients with newly diagnosed or recurrent malignant glioma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have